- Kymera Therapeutics press release ( NASDAQ: KYMR ): Q4 GAAP EPS of -$0.60 beats by $0.03 .
- Revenue of $16.1M (+5.4% Y/Y) misses by $4.56M .
- As of December 31, 2022, Kymera had approximately $559.5M in cash, cash equivalents, and investments.
- Kymera expects that its cash and cash equivalents will provide the company with an anticipated cash runway into the second half of 2025 that is expected to take the company past the proof-of-concept Phase 2 data for KT-474, as well as early proof-of-concept data for KT-413, KT-333 and KT-253, while Kymera continues to identify opportunities to accelerate growth and expand its pipeline, technologies, and clinical indications.
For further details see:
Kymera Therapeutics GAAP EPS of -$0.60 beats by $0.03, revenue of $16.1M misses by $4.56M